Cancer Summit

Precision Oncology and Personalized Cancer Therapy

Precision oncology is transforming modern cancer care by shifting treatment strategies from a one-size-fits-all approach to highly individualized therapeutic models based on a patient’s genetic, molecular, and biomarker profile. Advances in next-generation sequencing (NGS), comprehensive genomic profiling, and biomarker-driven diagnostics now allow clinicians to identify actionable mutations in tumors and match patients with targeted therapies that improve response rates and reduce unnecessary toxicity. Current trends include the rapid expansion of companion diagnostics, tumor-agnostic therapies, and molecular tumor boards that integrate multidisciplinary expertise to design personalized treatment plans. The growing use of liquid biopsy technologies enables real-time monitoring of tumor evolution, minimal residual disease detection, and therapy resistance assessment without invasive procedures. Immunotherapy biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and microsatellite instability (MSI) are playing a crucial role in guiding immune checkpoint inhibitor therapies. Furthermore, artificial intelligence and big data analytics are enhancing predictive modeling for treatment outcomes, optimizing drug selection, and accelerating precision drug development. The integration of pharmacogenomics into routine oncology practice is also helping to tailor drug dosing and minimize adverse reactions. As healthcare systems adopt value-based care models, precision oncology contributes to cost-effectiveness by improving therapeutic efficiency and avoiding ineffective treatments. Ongoing research in multi-omics approaches—including genomics, proteomics, and metabolomics—is expected to further refine individualized cancer management strategies. This session will explore emerging innovations, clinical applications, regulatory considerations, and translational research advancements that are shaping the future of personalized cancer therapy and redefining global oncology standards.